Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Pamiparib · 1 trial · 5 indications
Determine the RP2D of the pamiparib and surufatinib combination
The percentage of patients alive without documented progression 6 months after treatment initiation.
| Arm | Type | Description |
|---|---|---|
| Pamiparib + Surufatinib (Phase Ib/II) | EXPERIMENTAL | Phase Ib: A dose de-escalation schedule is used in the phase Ib dose finding part. Dose Level 1 (starting dose): pamiparib 40 mg administered orally twice daily (fixed dose) and surufatinib 250 mg administered orally once daily on a 21-day treatment cycle. If ≥2/6 patients experience a dose limiting toxicity (DLT), we will de-escalate to Dose Level 2: pamiparib 40 mg administered orally twice daily (fixed dose) and surufatinib 200 mg administered orally once daily on a 21-day treatment cycle. Approximately 3-12 patients will be enrolled in phase Ib study. Phase II: The phase II part will begin once the recommended phase 2 dose (RP2D) of surufatinib have been determined in the Phase Ib in order to assess antitumor activity of pamiparib and surufatinib combination. In phase II study, pamiparib 40 mg orally twice daily and surufatinib PR2D will be administered. |
| Name | Type | Description |
|---|---|---|
| Pamiparib | DRUG | Oral |
| Surufatinib | DRUG | Oral |
Inclusion Criteria: 1. Signed Informed Consent Form; 2. Histologically confirmed epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer; 3. Platinum-resistant disease, defined as progression within 6 months from completion of most recent platinum-containing therapy. Subject ...
Top 20 of 59 competitors
Pamiparib is an investigational small molecule being studied for the treatment of ovarian cancer, specifically platinum-resistant ovarian cancer. It is being evaluated in combination with surufatinib in patients with this condition. The drug is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
Pamiparib is being developed by HUTCHMED (China) Limited, a biopharmaceutical company listed on the stock exchange under the ticker HCM. The company is conducting clinical trials to evaluate the safety and efficacy of Pamiparib in patients with ovarian cancer.
Pamiparib is in Phase 1 clinical development. A Phase 1 trial has been completed, which enrolled 29 patients with platinum-resistant ovarian cancer. The drug is still investigational and has not received FDA approval or any other regulatory approval for commercial use.
Pamiparib has been studied in one clinical trial with the identifier NCT05494580. This Phase 1 trial, titled 'Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer,' was completed in China. The study enrolled 29 female patients aged 18 years and older with ovarian cancer or related conditions.
Pamiparib is a small molecule that targets PARP, an enzyme involved in DNA repair. By inhibiting PARP, Pamiparib may prevent cancer cells from repairing their DNA, leading to cell death. This mechanism is being explored in the treatment of platinum-resistant ovarian cancer, where the drug is combined with surufatinib.